RxDoctor Payments Data

Harold Milstein, MD

Dermatology · Philadelphia, PANPI 1083684344

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $81,385 of the $119,714 with a category attached, or 68.0%. 46 manufacturers reported payments, led by AbbVie at 55.3% of the total. Reporting peaked in 2019 at $52,467 and has fallen 92.7% since, to $3,846 in 2025. Among dermatology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$119,714in general payments, 2019–2025

Across 995 payments — averaging $120.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$66K
  • Novartis$24K
  • Sanofi$4K
  • Pfizer$4K
  • Boehringer Ingelheim$4K
  • LNHC, Inc$3K
  • plus $14K from 40 others

What the payments were for

  • Consulting fees$16,48514%
  • Speaking & faculty fees$81,38568%
  • Travel & lodging$1,8472%
  • Food & beverage$19,70916%
  • Education$2880%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$119,714 in reported general payments places this provider in the 95th percentile of 626 dermatology providers in Pennsylvania.

See all dermatology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$24,158
Medicare patients
74
Services billed
366

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa13$260,131
Cosentyx (2 Syringes)Secukinumab14$129,286
Cosentyx Sensoready (2 Pens)Secukinumab12$91,575
Humira(Cf) PenAdalimumab12$88,703
Dupixent PenDupilumab23$82,967
Clobetasol Propionate30$2,337
Ketoconazole78$1,438
Metronidazole19$1,321
Triamcinolone Acetonide77$1,024
Doxycycline Monohydrate49$930
Clindamycin Phosphate20$878
Betamethasone Dipropionate26$765
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip37$685
ValacyclovirValacyclovir Hcl17$599
Hydrocortisone49$565

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisCosentyx (2 Syringes)$24,219$129,28614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 626 dermatology providers in Pennsylvania.

Other dermatology in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →